Eli Lilly’s unique experimental antibody cocktail, which works as a preventive dose has also been surrounded by controversies ever since US President Donald Trump praised its efficacy rates after he was dosed with the same medicines during his treatment. While the cocktail drug combination, Regeneron is still in phase II study, the company announced that the trials have been brought to a pause, after a safety concern was discovered. Citing the safety concern, a statement from the company’s representative said,
“Out of an abundance of caution, the ACTIV-3 independent data safety monitoring board (DSMB) has recommended a pause in enrollment,”
The preventive shot, which is one of a kind makes use of monoclonal antibodies, manufactured after retrieving information from a recovered COVID patient. While antibody therapies are considered to be a safer bet than experimental vaccines, since they directly empower the immunity, Eli Lilly’s recent flaw discovery has only proved that no one therapy can be trusted on fully, in our fight against COVID-19.